Italy Cardiovascular Diseases Therapeutics Market Analysis

Italy Cardiovascular Disease Therapeutics Market Executive Analysis

The Italy cardiovascular disease therapeutics market size is at around $3.9 Bn in 2022 and is projected to reach $6.5 Bn in 2030, exhibiting a CAGR of 6.72% during the forecast period. The National Health Fund (NHF), which will increase from $130 Bn to $132 Bn in 2022, $133 Bn in 2023, and $137 Bn in 2024 owing to the 2022 Finance Act of Italy, has received an extra $2.14 Bn over the next three years. Additionally, the budget set aside for the acquisition of novel medications will rise by $107 Mn in 2022, $214 Mn in 2023, and $321 Mn in 2024. The overall cap on public expenditure on pharmaceuticals will rise from 14.85% to 15% of the NHF in 2022, to 15.15% in 2023, and to 15.3% starting in 2024.

With 60 Mn people, cardiovascular diseases cause nearly half (44%) of all casualties in Italy. The second largest cause of death (28%) is ischemic heart disease, and the third (after cancer) is cerebrovascular disease. The comparatively low standard of care offered by treating doctors has frequently been cited as a major contributor to the insufficient control rates of major CV risk factors. This appears to be related, among other things, to constraints on time during clinical consultations, a lack of understanding of and adherence to suggestions in guidelines, and a lack of timely and coordinated pharmacological and nonpharmacological interventions.

Due to pathophysiological and pharmacological synergisms, combination therapy regimens are more successful than up-titrating one antihypertensive agent (monotherapy), and this therapeutic approach is now advised as first-line therapy to reach the advised blood pressure (BP) goals in Italy. The most frequently advised combinations include calcium channel blockers (CCBs), a diuretic of the Thiazide/Thiazide-like variety, and angiotensin receptor blockers (ARBs) or angiotensin-converting enzyme inhibitors (ACEi). The first-line drug approach involves using statins at various doses and powers depending on LDL-c levels and estimated CV risk. In Italy, combination therapy using a statin and ezetimibe is advised if the objectives cannot be met with the highest tolerated dose of statin monotherapy. A combination with a PCSK9 inhibitor is advised for secondary prevention in patients who are very likely to not reach their target while taking a maximum tolerated dose of ezetimibe and a statin. For individuals with familial hypercholesterolemia at very high risk who do not meet their objectives on a maximum tolerated dose of statin and ezetimibe, PCSK-9 inhibitors are also advised for primary prevention.

Market Dynamics

Market Growth Drivers

A greater prevalence of cardiovascular diseases is being caused by Italy's aging population. The demand for therapeutics and treatments for cardiovascular illnesses is being driven by this. The general population in Italy is becoming more and more conscious of the risk factors for cardiovascular diseases. The Italy cardiovascular disease therapeutics market is expanding as a result of more people pursuing early diagnosis and treatment. The Italian government has launched a number of initiatives to encourage cardiovascular disease awareness and public health. These programs are designed to enhance public health generally and minimize the burden of cardiovascular diseases.

Market Restraints

Therapeutics for cardiovascular disease are comparatively expensive in Italy, which might prevent some patients from receiving these treatments. As a result, the Italy cardiovascular disease therapeutics market's development may be constrained by lower adoption rates. With numerous established companies and recent entrants competing for market share, the therapeutics market for cardiovascular disease in Italy is extremely competitive. As a result, there may be a strain on prices and profit margins, which could slow the market's expansion. Some treatments for cardiovascular diseases have risks and side effects that may prevent their widespread use. Because patients and healthcare professionals may choose to use safer or more efficient treatments, this may restrict the market's development.

Competitive Landscape

Key Players

• Mipharm (ITA)
• Pharmatex Italia (ITA)
• Farmaka (ITA)
• Meda Pharma (ITA)
• Truffini & Reggè Farmaceutici (ITA)
• Bristol-Myers Squibb
• Pfizer
• Bayer
• Janssen Pharmaceuticals
• AstraZeneca
• Sanofi

Healthcare Policies and Regulatory Landscape

All citizens and legal residents in Italy are covered by the country's publicly financed healthcare system. Healthcare services and treatments, including those for cardiovascular illness, are provided by the National Health Service (also known as the SSN or Servizio Sanitario Nazionale). Regarding payment guidelines for therapies for cardiovascular disease, the SSN typically covers medicines and procedures that are thought to be secure and efficient. The Italian Medicines Agency's (AIFA) formulary, which includes a catalog of medications covered by the SSN, is the foundation for the reimbursement policy. The AIFA formulary lists a variety of medications for the management of cardiovascular disease, including statins, antihypertensives, anticoagulants, and antiplatelets. Additionally, the list of choices lists medical supplies like pacemakers and stents. The severity of the illness and the patient's clinical state is taken into account when determining compensation for cardiovascular disease treatments in Italy. therapies for milder cases may not always be covered by the SSN, whereas therapies for more severe and acute cases are. In Italy, patients must make a co-payment for some treatments, including some for cardiovascular illness. The cost of the co-payment is determined by the type of therapy and patient income.